BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the ind

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerat

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerat

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and por

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estim

Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analy

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing

First Trust Advisors LP boosted its stake in Pacira BioSciences, Inc. (NASDAQ: PCRX) by 59.2% in the

With drug product from the new manufacturing process now available, the first patient has been enrol

— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product f

Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been assigned an average re

BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the ind

BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the ind

PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- B

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management  Across Outpatient Settings -- 

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million

BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company

Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2

Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Lead

ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissi

First quarter 2026 revenue up 79.4% compared to the first quarter of 2025 First quarter 2026 gross p

BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Com

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewe

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in mi

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analy

The data were presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hoste

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight a

U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining

Activist investor DOMA nominates three directors to Pacira's board, citing weak oversight, misse

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the L

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term

Pacira BioSciences (NASDAQ:PCRX) sees FY2026 sales of $745.000 million-$770.000 million vs $790.214

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.57 per share which missed the ana

-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioi